Sanofi (SAN), France’s biggest drugmaker, is seeking more deals with venture-capital funds like its partnership with biotechnology company Warp Drive Bio, Chief Executive Officer Chris Viehbacher said.
Sanofi teamed with venture-capital firms Third Rock Ventures and Greylock Partners last year to finance Warp Drive Bio, which is using genomic technology to develop new treatments. The Paris-based drugmaker has recruited someone to look at venture-capital projects, though Viehbacher declined to identify the person.
“The Warp Drive model where we are doing in-kind contributions for equity, where our researchers are directly involved in the project, that’s to me more where we want to go,” Viehbacher said in an interview in Lyon, France. “I don’t want to have a portfolio of assets over here and then research and development projects over there.”
To read the full, original article click on this link: Sanofi to Seek More Venture-Capital Deals Like Warp Drive - Businessweek
